Clicky

UCB SA(UCBJF)

Description: UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.


Keywords: Medicine Biopharmaceutical Clinical Medicine Monoclonal Antibodies Parkinson's Disease Rheumatoid Arthritis Arthritis Psoriasis Osteoporosis Epilepsy Crohn's Disease Rheumatology Allergies Systemic Lupus Erythematosus Psoriatic Arthritis Immunosuppressants Plaque Psoriasis Myasthenia Gravis Seizure Immune Thrombocytopenia Ankylosing Spondylitis Chronic Inflammatory Demyelinating Polyneuropathy Treatment Of Osteoporosis Hidradenitis Suppurativa Severe Diseases Immunology Diseases Restless Legs Syndrome Certolizumab Pegol Cimzia Keppra Neupro Ucb Vimpat Alprazolam Contract Manufacturing Activities Drug Resistant Epilepsy Immune Mediated Necrotizing Myopathy Inflammatory Tnf Mediated Diseases Progressive Supranuclear Palsy Tauopathies Xyzal Zyrtec Active Epileptic Seizure Therapies And Solutions

Home Page: www.ucb.com

AllEe de la Recherche, 60
Brussels, 1070
Belgium
Phone: 32 2 559 99 99


Officers

Name Title
Dr. Jean-Christophe Tellier CEO & Executive Director
Ms. Sandrine Dufour CFA Executive VP, CFO & Chief Corporate Development
Dr. Kirsten Lund-Jurgensen Ph.D. Executive Vice President of Supply & Technology Solutions
Ms. Denelle J. Waynick Johnson J.D. Executive VP & General Counsel
Mr. Jean-Luc Fleurial Executive VP & Chief Human Resources Officer
Mr. Emmanuel Caeymaex Executive VP & Chief Commercial Officer
Ms. Fiona du Monceau Executive Vice President of Patient Evidence
Ms. Caroline Vancoillie Chief Accounting Officer, Head of Group Finance & CFO of Patient Value Functions
Mr. Alistair Henry Executive VP & Chief Scientific Officer
Ms. Antje Witte Head of Investor Relations

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 23.4742
Trailing PE: 134.8837
Price-to-Book MRQ: 3.5096
Price-to-Sales TTM: 6.6233
IPO Date:
Fiscal Year End: December
Full Time Employees: 9000
Back to stocks